Advisor Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Advisor Group’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	80	–	–	﹤0.01%	5505
2019 Q3	$0	Hold	80	–	–	﹤0.01%	5489
2019 Q2	$0	Sell	80 -32	-29%	-$244	﹤0.01%	5422
2019 Q1	$1K	Hold	112	–	–	﹤0.01%	5142
2018 Q4	$0	Buy	112 +63	+129%	+$908	﹤0.01%	5297
2018 Q3	$1K	Buy	49 +30	+158%	+$546	﹤0.01%	5026
2018 Q2	$0	Sell	19 -250	-93%	-$3.69K	﹤0.01%	5093
2018 Q1	$3K	Hold	269	–	–	﹤0.01%	4613
2017 Q4	$12K	Buy	269 +172	+177%	+$7.72K	﹤0.01%	4007
2017 Q3	$6K	Buy	97 +20	+26%	+$3.37K	﹤0.01%	4229
2017 Q2	$14K	Buy	77 +45	+141%	+$7.89K	﹤0.01%	3754
2017 Q1	$4K	Buy	32 +25	+357%	+$2.62K	﹤0.01%	4233
2016 Q4	$1K	Sell	7 -62	-90%	-$6.53K	﹤0.01%	4424
2016 Q3	$8K	Buy	+69	New	+$8.28K	﹤0.01%	3708

Other funds holding SIOX

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Advisor Group's SIOX Position: Q4 2019 in Review

Advisor Group held its Sio Gene Therapies Inc. Common Stock (SIOX) position steady in Q4 2019 at 80 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5505.

Advisor Group first reported a position in SIOX in Q3 2016 and has held it in 14 quarters since. The position peaked at $14K in Q2 2017. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2019.

Advisor Group held 80 shares of Sio Gene Therapies Inc. Common Stock worth $0 as of Q4 2019.
Advisor Group left its Sio Gene Therapies Inc. Common Stock share count unchanged in Q4 2019.
Sio Gene Therapies Inc. Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5505 holding.
Advisor Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2016 and has held it in 14 quarters since.
Advisor Group's Sio Gene Therapies Inc. Common Stock position peaked at $14K in Q2 2017.
48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.